SUO 2018: The Case for Neoadjuvant Immunotherapy
Phoenix, Arizona (UroToday.com) Dr. Necchi started his talk by pointing out that cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care (SoC) for muscle-invasive bladder cancer (MIBC) but the adherence to SoC is poor, and there are no good predictive biomarkers. Therefore, there is a need for other agents possibly immuno-oncology (IO) drugs. He highlighted the study by Forde et al. in NEJM in lung cancer patients, where neoadjuvant nivolumab was used and was associated with few side effects, did not delay surgery, and induced a significant pathological response in 45% of resected tumors.
SUO 2018: The Case for Adjuvant Immunotherapy
Phoenix, Arizona (UroToday.com) Dr. Steinberg began his talk by highlighting all the FDA approved checkpoint inhibitor therapies in metastatic urothelial cancer following cisplatin. The use of immune-oncology (IO) agents has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma. Antibodies directed against the checkpoints ‘programmed cell death 1’ (PD-1) and ‘programmed death ligand 1’ (PD-L1) were shown to induce rapid and durable responses in advanced urothelial in the salvage setting and for patients in the first line-setting who are cisplatin-ineligible.
SUO 2018: Adaptive Survival Pathways – AR Variants and Autophagy
Phoenix, Arizona (UroToday.com) Christopher Evans discussed co-targeting Adaptive Survival Pathways in mCRPC, with a specific focus on AR variants and autophagy. The basis of this lies in the wealth of opportunities that come with targeting the AR axis – it still remains the predominant target for prostate cancer management. Yet, with more research, we are learning more about concurrent pathways that affect the AR axis that can be targeted for therapeutic purposes.
SUO 2018: Preclinical Models in Bladder Cancer and Translational Research
Phoenix, Arizona (UroToday.com) At the Bladder Cancer Session II at SUO 2018, Dr. James M. McKiernan, Chairman of Urology and Director of Urologic Oncology at Columbia University, New York, NY, presented an overview of preclinical models in bladder cancer and translational research.
SUO 2018: Uptake on PSMA Targeted Alpha Emitters in mCRPC
Phoenix, Arizona (UroToday.com) Prostate-specific membrane antigen (PSMA), a cell surface enzyme, has high and consistent expression in metastatic prostate cancer (PCa) and relatively low or no expression in normal prostate cells. Furthermore, it has been established that attenuated androgen receptor (AR) signaling is a hallmark of lethal prostate cancer, and AR signaling pathway activity is inversely related to PSMA expression. Therefore, PSMA has consequently become a target of interest for targeted radioligand therapy, especially in metastatic castrate-resistant prostate cancer (mCRPC).
SUO 2018: Signal Transduction Pathways – ADT + AKT trials
Phoenix, Arizona (UroToday.com) The tumor suppressor PTEN is the gate keeper of the PI3K pathway, regulating down-stream signaling and protein expression. It is lost in 20% of prostate cancers and in 40% of castrate resistant prostate cancers (CRPC), and its loss has been shown to drive prostate tumorigenesis and result in aggressive prostate cancer resulting in the castrate resistant phenotype.
SUO 2018: Long-term Patient Reported Outcomes with Abiraterone Acetate+prednisone Added to Androgen Deprivation Therapy in Newly-diagnosed Metastatic Castration-naïve Prostate Cancer: Second Interim Analysis of the Latitude Study
Phoenix, Arizona (UroToday.com) The LATITUDE study, published in July 2017, was a phase III randomized, clinical trial that evaluated that evaluated the efficacy of abiraterone acetate and prednisone with androgen deprivation therapy (ADT) in men with newly-diagnosed, castration sensitive, metastatic prostate cancer.